hosts.  c signaling in the tumor-bearing host was important for survival and proper differentiation of adoptively transferred tumor-specific CD4 + T cells. Thus, these data provide a platform for designing immunotherapies that incorporate tumor/self-reactive CD4 + T cells.
Adoptive cellular therapy (ACT) of cancer using in vitro differentiated CD8 + T cells is a power ful treatment against established cancer in humans and mice. In recent years, great progress has been attained in the understanding of the mechanisms involved in enhancing treatment of large established tumors (Gattinoni et al., 2006) . Lymphodepletion before adoptive ther apy greatly enhances ACT in humans and mice through the creation of cytokine sinks, removal of regulatory T cells (T reg cells), and the re lease of tolllike receptor agonists (Gattinoni et al., 2005a; Paulos et al., 2007; Dudley et al., 2008) . Recent evidence suggests that irradia tion also enhances the expression of ICAM and VCAM in the tumor vasculature allowing tu morreactive T cells to enter more readily (Quezada et al., 2008) . Although CD8 + T cells are potent mediators of antitumor immunity, there has been little focus on tumorspecific CD4 + T cells. CD4 + Th cells are important in immunity because in the absence of help, CD8 + T cells can be deleted or lose the capacity to develop into memory CD8 + T cells upon re challenge (Janssen et al., 2003; Antony et al., 2005; Williams et al., 2006) . Therefore, the use of tumor/selfreactive CD8 + T cells in the adoptive immunotherapy of cancer may face similar fates because T cells must remove tumor antigen in the context of persisting selfantigen, which in some cases leads to autoimmunity (Gattinoni et al., 2006; Rosenberg et al., 2008) . Adoptive cell therapies that incorporate CD4 + is expressed in malignant melanoma and in the skin and eyes of mice and humans; therefore, this model mimics the human condition as closely as possible. Surprisingly, we found that adoptive transfer of naive TRP1-specific CD4 + T cells into lymphopenic animals bearing large established melanoma caused tumor regression and depigmentation independent of vaccination, cytokine administration, and CD8 + , B, NK, and NKT cells. This therapy was dependent on common gamma chain ( c ) signaling in the host for survival and differentiation of CD4 + T cells in vivo. These data provide a better under standing for the design of immunotherapies that incorporate tumor/selfreactive CD4 + T cells.
RESULTS
Autoimmunity and cancer regression with adoptive transfer of naive tumor-specific TRP-1 CD4 + T cells into lymphopenic mice TRP1-specific CD4 + TCR Tg mice were created on a C57BL/6 background that contains TRP1 as a selfantigen (Muranski et al., 2008) . These mice develop vitiligo (depig mentation) slowly with age ( Fig. S1 A) but can develop vitiligo rapidly with genetic removal of Foxp3 (denoted Foxp3 sf ), which is required for development of T reg cells that suppress autoimmune disease  Fig. 1 A and Fig. S1 B) . TRP1-specific CD4 + TCR Tg mice, which express TRP1 antigen, have activated T cells that are characterized by low expression of CD62L and high expression of CD44 on TRP1 CD4 + T cells in vivo ( Fig. S1 C, top) . Because we wanted to study naive CD4 + T cells, Tyrp1 +/+ TRP1 CD4 + Tg mice were crossed with whitebased brown mutation mice (Tyrp1 B-w ) containing a radiationinduced inversion interrupting the tyrp1 gene (Smyth et al., 2006) . RTPCR confirmed that no Tyrp1 messenger RNA (mRNA) was present in Tyrp1 B-w mice, and Tyrp1 B-w mice that express the Tg TCR do not develop vitiligo (unpublished data). These mice have a lightbrown coat color (Fig. S1 D) and were further crossed with RAG / mice to generate naive monoclonal TRP1-specific CD4 + T cells ( Fig. S1 C, bottom ). This mouse model is unique in that it develops T cells specific for TRP1 that are both Foxp3  and Foxp3 + on a RAG / background. The ex pression of Foxp3 is at the natural physiological ratio of 5-15% ( Fig. S1 E) .
Once TRP1-specific CD4 + TCR Tg mice on a Tyrp1 B-w RAG / background were obtained (hereafter denoted as TRP1 CD4 + T cells), TRP1 CD4 + T cells were transferred into nontumorbearing RAG / mice and observed for signs of specific immunity (e.g., depigmentation). Indeed, 5-6 wk after transfer, the mice developed progressive depigmenta tion as indicated by coat color changes from black to white (Fig. 1 B) . Depigmentation progressed until the mice became completely white.
To determine if adoptive transfer of TRP1 CD4 + T cells could mediate the regression of established tumors, WT, RAG / , and irradiated WT mice (5 Gy) were given 2 × 10 5 B16 tumor cells s.c. On day 7, after tumor was visible and palpable, sorted TRP1 CD4 + T cells from 2 × 10 5 Tyrp1 B-w RAG / mice were transferred i.v. by tail vein injection into T cells are far superior to therapies that only use CD8 + T cell clones (Dudley et al., 2002) . Therefore, one theoretical means of improving immunotherapy to self may involve the provision of tumorreactive or selfreactive CD4 + T cells (Nishimura et al., 1999; Marzo et al., 2000; Antony et al., 2005) , but a more direct role for CD4 + T cells in tumor immunity remains unclear (Ho et al., 2002; Muranski and Restifo, 2009) .
Recently, adoptive transfer of in vitro differentiated tumorspecific CD4 + T cells in humans and mice has shown promise against cancer as a therapy (Nishimura et al., 1999; PerezDiez et al., 2007; Hunder et al., 2008; Muranski et al., 2008) . This has rekindled the idea of using antigenspecific CD4 + Th during immunotherapy because CD4 + Th cells can mediate the proper signals required in vivo to activate CD8 + T cells and other cells of the innate immune system (Kahn et al., 1991; Hung et al., 1998; Nishimura et al., 1999; Antony et al., 2006; Williams et al., 2006) . In fact, several preclinical and clinical trials have shown the importance of CD4 help during immunotherapy of cancer (Nishimura et al., 1999; Antony et al., 2006; Dudley et al., 2008) . However, isolation of tumorspecific CD4 + T cells has been difficult (Wang, 2001) and only a few MHC class II vaccines have been pro duced as a result of the lack of knowledge of how to generate vaccines that specifically activate Th cells instead of tumor specific Foxp3 + T reg cells (Rosenberg, 2001; Vence et al., 2007) . In addition, lack of appropriate mouse models to study tumorspecific CD4 + T cell responses to selfantigens has hin dered progress in our understanding of the role of CD4 + T cells in maintaining immunity to cancer. Now, with a better understanding of CD4 + T cell biol ogy, the use of cytokines to differentiate and expand T cells in vitro has led to a panoply of CD4 lineages with specific in vivo functions (Weaver and Rudensky, 2009) . For example, in vitro differentiated CD4 + Th17 tumorspecific T cells have shown superiority over CD4 + Th1 differentiated T cells in the adoptive immunotherapy of cancer in a mouse model of melanoma (Muranski et al., 2008) . IL2 and IL7 in vitro expanded NYESO1-specific CD4 + T cells in humans have also shown clinical promise in one patient who had not received prior lymphodepleting conditioning or a vaccine (Hunder et al., 2008) . Although these are promising studies, the mechanisms involved in the direct therapy of cancer by CD4 + T cells remain elusive. Likewise, methods for enhanc ing adoptive immunotherapy without prior in vitro manipu lation that may lead to the terminal differentiation of T cells also remain unclear (Gattinoni et al., 2005b Klebanoff et al., 2005) . Although such manipulations can lead to vaccine independence (Klebanoff et al., 2009) , longterm benefits from in vivo differentiation may outweigh in vitro stimulation because the in vivo environment may provide the correct signals that cannot be attained in a culture dish.
To test a direct role for CD4 + T cells in the immuno therapy of cancer, we used a gp75/tyrosinaserelated protein (TRP) 1-specific CD4 + TCR transgenic (Tg) mouse that produces class II-restricted T cells that recognize mouse TRP1 in the context of IA b (Muranski et al., 2008) . TRP1
Figure 1. Treatment of established melanoma with adoptive transfer of TRP-1 CD4 + T cells into lymphopenic mice is specific. (A)
Enhanced specific autoimmune disease in TRP-1 CD4 + Foxp3 sf (Foxp3 negative) mice. TRP-1 CD4 + WT Tg mice (left; n = 13) and TRP-1 CD4 + Foxp3 sf mice (right; n = 7) were compared for incidence of depigmentation over time. 1-mo-old littermates are shown. TRP-1 CD4 + Foxp3 sf mice have no Foxp3 + T cells as shown by flow cytometry. (B) Depigmentation (vitiligo) can be adoptively transferred to lymphopenic hosts through TRP-1-specific CD4 + T cells. 2 × 10 5 TRP-1 CD4 + T cells from Tyrp1 B-w RAG / mice were transferred to nontumor-bearing RAG / hosts. Mice (n = 20) developed depigmentation after 35-45 d. A representative picture is shown. (C) Tumor-bearing WT mice were irradiated with 500 rads (5 Gy) or not irradiated (0 Gy) on day 7 after tumor challenge, and 2 × 10 5 naive TRP-1 CD4 + T cells were adoptively transferred by i.v. tail vein injection. Experiments were repeated two times. P < 0.0001 for WT mice receiving 5 Gy and TRP-1 CD4 + T cells versus no treatment. (D) Tumor-bearing RAG / mice were irradiated with 500 rads (5 Gy) or not irradiated (0 Gy) on day 7 after tumor challenge, and 2 × 10 5 naive TRP-1 CD4 + T cells were adoptively transferred by i.v. tail vein injection. Experiments were repeated nine times. P < 0.0001 for RAG / no treatment versus RAG / + TRP-1 CD4 + T cells (0 Gy or 5 Gy). (E) Whole body vitiligo in tumor-bearing mice treated with TRP-1 CD4 + T cells (n = 40 mice). (F) Tumor regression in lymphopenic mice treated with TRP-1 CD4 + T cells at days 10 and 49. The picture is representative of 40 mice over eight different experiments. (G) Adoptive transfer of 10 6 open repertoire CD4 + CD25  T cells into lymphopenic tumor-bearing RAG / mice on day 7 after tumor challenge does not affect tumor growth. Data represent three independent experiments. n = 5 mice/group; P = NS. Error bars indicate SEM. tumorbearing mice. Adoptive transfer of TRP1 CD4 + T cells into lymphopenic mice caused infiltration of tumor specific T cells into and regression of established tumors (Fig. 1, C and D; and Fig . S1 F). Irradiated WT mice had a transient antitumor response, indicating a temporary lym phodepletion as seen in mice and patients that are lympho depleted (Dudley et al., 2005; Gattinoni et al., 2005a; Zhang et al., 2005) .
Because we wanted to study the role of CD4 + T cells in tumor immunity, we focused on RAG / mice because these mice contain no CD8 + T cells, B cells, or NKT cells, all of which have been described in tumor immunity (Dougan and Dranoff, 2009) . Complete regression of B16 melanoma was observed in RAG / mice ( Fig. 1 D) . RAG / mice that received 5 Gy irradiation to deplete cytokine sinks (Gattinoni et al., 2005a) and adoptive cell transfer of TRP1 CD4 + T cells also had complete regression. As seen in non tumorbearing RAG / mice, depigmentation was present in tumorbearing RAG / mice at 5-wk after treatment ( Fig. 1 E) . Tumor regression was dramatic, with large estab lished tumors regressing to a small scar ( Fig. 1 F) . RAG / mice do not have endogenous CD8 + T, B, or NKT cells; therefore, this therapy was completely independent from these cell types. Because TRP1 CD4 + T cells came from Tyrp1 B-w RAG / mice, there was no concern for contamina tion from other cells that may contribute to tumor therapy.
To determine whether tumor treatment in lymphopenic hosts was specific, we sorted "openrepertoire" CD4 + CD25  T cells from WT mice and transferred 10 6 CD4 + T cells into RAG / mice on day 7 after tumor inoculation ( Fig. 1 G) . CD4 + CD25  T cells have virtually no Foxp3 + T cells and have been shown to help tumorspecific CD8 + T cells main tain treatment of established tumors without the addition of exogenous cytokines (Antony et al., 2006) . However, by themselves, CD4 + CD25  openrepertoire T cells did not affect tumor growth in lymphopenic mice. Therefore, we conclude that TRP1 CD4 + T cells are specific for their tumor/selfantigen in vivo and that the antitumor effect is independent of CD8 + , B, and NKT cells.
TRP-1 CD4 + T cells differentiate into Th1 cytotoxic T cells in lymphopenic mice
Because it has been shown that in vitro differentiated Th17 tumorspecific T cells were superior to other CD4 + T cell lineages when treating established tumors (Muranski et al., 2008) , we wanted to determine the in vivo default differenti ation program that leads to strong tumor regression by TRP1 CD4 + T cells. After 1 wk in vivo, adoptively transferred CD4 + T cells were FACS sorted from tumordraining LNs and the spleens of mice undergoing tumor regression and an alyzed by gene microarray. These cells were compared with FACSsorted naive TRP1 CD4 + T cells. Only genes with a twofold or greater difference were displayed. As shown in Fig. 2 A, TRP1 CD4 + T cells transferred into a lymphope nic environment defaulted to a CD4 + Th1 program, as indi cated by high expression of Tbet, Ifng, Il18r, Il2r, Il12r (Th1 priming), Il23r (Th1 memory; Robinson and O'Garra, 2002) , Il27r (early Th1 priming), Tim3, Cxcr3, Ccr2, and Ccr5 mRNA, with evidence of some Th17associated genes (Il22, Il23r, and Rora) and Th2 genes (Il10 and gata3) but not Ccr6, Il4, Il5, Il17a, Il17f, or Rorc. Genes for TCR signaling were upregulated in the spleen (Lck and Zap70) but not in the LN, probably indicating recently activated trafficking T cells, suggested by increased Cd69, Cd5 (strong TCR signals), and Lat expression. Jak3 was upregulated in TRP1 T cells, indicating that  c signaling was active. Stat4 was highly expressed, demonstrating that IL12, and possibly IL23, signals were potentiating IFN production. Coactivation genes, including 41BB and ICOS, were highly upregulated. Both are involved in enhancing the activation of T cells (Tamada and Chen, 2006; Stephan et al., 2007; McNamara et al., 2008) . Genes related to CTL effector functions were increased; Gzmb, Gzmc, Gzmd, and Gzmk were highly up regulated, with only Gzmb and Gzmc staying at high levels in the spleen. Fasl was also upregulated.
Genes that regulate the expansion of T cells by control ling T cell activation in a negative manner-TgfrI, Ctla-4, Cish, Il10, and Socs2-were also upregulated ( Fig. 2 A) . High IFN levels were confirmed in the serum of lympho penic mice undergoing tumor treatment but not in WT mice or untreated lymphopenic RAG / mice (Fig. 2 B) . CXCR3 and ICOS, both Th1associated molecules, were also expressed by TRP1 CD4 + T cells (Fig. 2 , C and D).
Next, we looked at effector molecules in TRP1 CD4 + T cells and found perforin, granzyme B, and LAMP1 (CD107a), all of which are involved in degranulating cytotoxic T cells ( Fig. 3 ). Because TRP1 CD4 + T cells expressed granzyme B on gene array ( Fig. 2 ) and in the spleen (Fig. 3 ), these data suggest that the antitumor CD4 + T cells are cytotoxic. Thus, naive TRP1 CD4 + T cells differentiated into a Th1 pheno type in vivo and expressed cytotoxic T cell-associated genes and molecules that may assist in antitumor immunity.
Adoptive transfer of naive TRP-1 CD4 + T cells into lymphopenic mice changes chemokine expression patterns
CXCR3, CCR2, and CCR5 are chemokine receptors that help draw Th1 CD4 + T cells into inflamed tissues. Because we saw high chemokine receptor expression on TRP1 CD4 + T cells (Fig. 2 , A and C), we checked the serum of lympho penic and nonlymphopenic mice for the specific ligands and found high expression of IFN-inducible CXCL9 and CXCL10 (the ligands for CXCR3), as well as CCL2 (the ligand for CCR2) and CCL11 (the ligand for CCR2 and CCR5), in lymphopenic mice during tumor regression ( Fig.  2 E) . CCL3 (the ligand for CCR5) was also moderately high in the serum of lymphopenic mice during tumor regression (unpublished results). CCL2 is known to draw inflammatory monocytes from the blood into LN and activate Th1 CD4 + T cells (Nakano et al., 2009) . We saw accumulation of in flammatory monocytes (CD11b high GR1 + ) in the spleen, LN, and tumors of treated groups (Fig. S2 ). These cells are class II + and are known to secrete IFN that may help aid Th1 differentiation (Nakano et al., 2009) . Other chemokine re ceptors were upregulated on TRP1 CD4 + T cells, includ ing CXCR6, which is involved in trafficking to the spleen, and CCR9 ( Fig. 2 A) . Lastly, a multitude of inflammatory notreatment groups ( Fig. 4 B) , suggesting, as previously shown, that MHC class II is needed to prime naive CD4 + T cells (Beutner and MacDonald, 1998) . This implies that MHC class II expression on the tumor was not sufficient to activate naive CD4 + T cells. However, in vitro activated TRP1 CD4 + T cells can treat MHC class II + tumors in MHC class II / mice, and anticlass II antibodies can block this ef fect (see Quezada et al. in this issue) , showing that the func tion of activated CD4 + T cells is independent of host class II.
Next, to determine if tumor antigen alone is enough to activate TRP1 CD4 + T cells, tumorbearing female Tyrp1 B-w RAG / mice, which express no TRP1 antigen, were trea ted with TRP1 CD4 + T cells. In the absence of selfantigen in the periphery, tumor treatment was complete and irradia tion did not affect the antitumor response ( Fig. 4 C) . Even though the tumor may be able to express class II, these ex periments demonstrate that T cell activation by host MHC class II + cells may be essential for the success of treatment in the lymphopenic setting. These experiments also show that the tumor/selfantigen, TRP1, expressed only by the tumor, is adequate to activate naive TRP1 CD4 + T cells trans ferred into Tyrp1 B-w RAG / mice.
IFN has been attributed to the mechanism of action by which CD4 + T cells eradicate tumors (Mumberg et al., 1999; Nishimura et al., 1999; Corthay et al., 2005; Muranski et al., 2008) . We administered anti-IFN antibodies (500 µg/ mouse) once, at the time of adoptive cell transfer, and found that anti-IFN antibodies were able to attenuate the anti tumor response in lymphopenic mice ( Fig. 4 D) .
To determine why adoptive transfer of T cells resulted in activation of CD4 + T cells in RAG / mice, we looked at CD11c + DC activation status because these cells express high levels of MHC class II in vivo. We found, after adoptive cell transfer with TRP1-specific CD4 + T cells, that CD11c high DC expressed increased levels of MHC class II and CD86 chemokines were differentially expressed by TRP1 CD4 + T cells in the LN and spleen (Fig. 2 A) . Therefore, TRP1 CD4 + T cells activated by lymphopeniainduced prolifera tion may help trigger Th1 chemokines, which could enhance immunotherapy by recruiting inflammatory monocytes and CXCR3 + CCR2 + CCR5 + TRP1 CD4 + T cells to appropri ate sites for activation and tumor infiltration.
Mechanisms of activation and effector function of TRP-1 CD4 + T cells during lymphopenia
It is known that MHC class I is upregulated on tumor cells in vivo in the presence of IFN + tumorspecific CD8 + T cells . However, it is not known whether IFN enhances MHC class II expression on established tumors in vivo. Because we saw high levels of IFN exp ression in the serum and on gene microarray, we evaluated the expression of MHC class II in the tumor microenviron ment. 1 wk after adoptive transfer with TRP1 CD4 + T cells, lymphopenic mice were sacrificed and tumors were imaged for MHC class II expression by confocal microscopy. Lym phopenic mice that had received no TRP1 CD4 + T cells had no evident expression of MHC class II on tumor cells in vivo. However, in mice that had received TRP1 CD4 + T cells, MHC class II expression was highly expressed on tumor cells in vivo ( Fig. 4 A) . To our knowledge, this is the first time class II upregulation in vivo by B16 melanoma has been reported. This may be similar to the mechanism of in duction of MHC class II reported in certain autoimmune diseases (Belfiore et al., 1991) .
To determine if host MHC class II was important in activating TRP1 CD4 + T cells in mice with MHC class II +/+ tumors, tumorbearing irradiated and nonirradiated MHC class II / mice were treated with naive TRP1 CD4 + T cells. Mice were irradiated to mimic the lymphopenic environ ment. Tumor treatment in both groups was comparable to the when compared with nontreated groups (Fig. 4 E) . Collectively, these experiments suggest that adoptively transferred TRP1 CD4 + T cells become activated on host MHC class II + cells and may eradicate tumors through an IFN-dependent pathway that may be linked to MHC class II expression on the tumor.
Activation, persistence, and memory formation of TRP-1 CD4 + T cells
To determine how lymphopenia affects longterm mainte nance and memory formation of Th1 CD4 + T cells, we ana lyzed TRP1 CD4 + T cells from mice undergoing long term tumor therapy (270 d). It may be possible that in vivo differentiation might bestow upon T cells a signal that allows them to persist and become superior antitumor CD4 + T cells. Therefore, we looked at longterm mainte nance and found that adoptively transferred TRP1 CD4 + T cells can maintain tumor regression and persist at rela tively high levels 270 d after transfer (Fig. 5, A and B) . We also looked at memory formation and activation markers that differentiate between effector memory T cells (TEMs) and central memory T cells (TCMs). CD62L and CD44 were high and low, respectively, as expected before transfer of CD4 + T cells (Fig. 5 C) . Naive T cells were also IL 7R high (Fig. 5 D) . After 1 wk, CD4 + T cells became acti vated as shown by the phenotype CD62L low , CD44 high , and IL7R low (Fig. 5, C and D) . Mice were analyzed for adop tively transferred T cells again 270 d later. CD4 + T cells remained at high levels and were mostly TEM (CD62L low transferred TRP1 CD4 + T cells into RAG /  c / hosts, which lack NK cells in addition to T, B, and NKT cells (Cao et al., 1995) . Previously, it was shown that treatment of a 1d tumor was hindered in RAG /  c / mice (Perez Diez et al., 2007) , and this was attributed to a lack of NK cells. In agreement with the previous study, we found that tumor therapy was hindered even when supplemented with irradiation ( Fig. 6 A) . To examine this further, we depleted NK cells in tumorbearing RAG / mice starting on days 0 and 7 after tumor challenge, 1 d after ACT, and then weekly. TRP1 CD4 + T cells were transferred into tumorbearing RAG / mice on day 8. We found that NK1.1 depletion (1 mg of antiNK1.1/mouse) did not af fect tumor treatment in a negative manner (Fig. 6 B) . We also irradiated RAG / mice with 5 Gy. The results were similar to those associated with NK cell depletion ( Fig. 6 A) . Next, we transferred 5 × 10 6 sorted NK cells into RAG /  c / mice along with TRP1 CD4 + T cells. Treatment was similar to RAG /  c / mice with TRP1 CD4 + T cells alone (Fig. 6 C) . and CD44 high ), but 12% of CD4 + T cells were TCM (CD62L high and CD44 high ; Fig. 5 C) .
To assess whether TRP1 selfreactive T cells converted to T reg cells over this time span, we looked at Foxp3 expres sion in adoptively transferred cells and found that in long term responder mice, Foxp3 expression remained stable at 5-15% (Fig. S3 ). Mice also became completely depigmented (Fig. 5 E) . Lastly, granzyme B, IFN, and TNF were evident in TRP1 CD4 + T cells 120 d after transfer, indicating that they were effector T cells (Fig. 5 F) . Therefore, tumor specific CD4 + T cells differentiated in vivo can persist for long periods of time and appear to continue to clear antigen based on the progressive depigmentation, granzyme B expression, and TEM phenotype. TRP1 CD4 + TCM cells may also renew the TRP1 CD4 + TEM pool over time.
NK cells are not required for tumor therapy with TRP-1 CD4 + T cells
To determine host mechanisms that affect the activation and persistence of adoptively transferred CD4 + T cells, we 
DISCUSSION
ACT using a patient's own immune cells to treat established cancer has been highly successful therapy against melanoma (Rosenberg et al., 2008) and is increasingly being used against other cancers as well (Stephan et al., 2007; Pule et al., 2008) . ACT using CD4 + T cells was recently attempted in a patient with metastatic melanoma using NYESO1-specific CD4 + T cells expanded in vitro in IL7 and IL2 (Hunder et al., 2008) . Surprisingly, adoptive transfer therapy with CD4 + T cells led to objective cancer regression without prior vacci nation or lymphoconditioning. Although this was reported in only one patient, the findings support the possibility of treating established tumors without vaccination or radiation therapies that may cause extended morbidity in patients with prolonged and severe sickness. In the prior study, epitope spreading was reported as the likely cause of the enhanced treatment, indicating that CD4 + T cells helped a CD8 + T cell response to the established tumor as shown in preclinical models (Marzo et al., 2000; Antony et al., 2006) . In this pa per, we describe a CD8 + T cell-and vaccineindependent therapy in which in vivo differentiated Th1 CD4 + T cells recognize self and eradicate established tumors.
Although we focused on a naive T cell-and a vaccine independent therapy, we do not advocate that vaccines are ineffective or that in vitro differentiation of T cells should not be attempted. Recently, it was shown that a tumor vaccine was required to enhance the immunotherapy of cancer when using in vitro-activated antitumor CD8 + T cells and CD4 + Th cells (Overwijk et al., 2003; Antony et al., 2005) . Vaccine independence was seen only after extreme radiation therapy (9 Gy) before ACT or in vitro programming of TEM cells Klebanoff et al., 2009) . The impor tance of activating CD4 + T cell help with a tumor vaccine has also been strengthened of late. A study using a modified TRP1 vaccine could induce either tumor immunity or auto immunity depending on the modification in the vaccine (Engelhorn et al., 2006) . When the modified vaccine acti vated CD4 + T cell help through enhanced processing of MHC II peptides, tumor immunity was induced (Engelhorn et al., 2006) . This new strategy to stimulate CD4 + T cells against self emphasizes the need to understand how CD4 + T cells become activated in vivo.
In this study, we demonstrate that naive CD4 + T cells transferred into lymphopenic hosts differentiated into Th1 cytotoxic T cells expressing the hallmark genes associated with effector T cells-Tbet, IFN, CXCR3, granzyme B, perforin, and LAMP1-and caused the regression of estab lished tumors without the aid of CD8 + T, B, NK, or NKT cells. CD4 + T cells have been shown to play a role in cancer immunotherapy through a multitude of mechanisms; CD4 + T cells can help cytotoxic CD8 + T cells eradicate tumors (Hung et al., 1998; Nishimura et al., 1999; Toes et al., 1999; Sutmuller et al., 2001; Behrens et al., 2004a,b; Antony et al., 2005; Engelhorn et al., 2006; Brandmaier et al., 2009) , and CD4 + T cells can condition a DC through CD40L to en hance CD8 + CTL function (Bennett et al., 1998; Kalams and NK cells are required for efficient priming and activation of CD4 + T cells in vivo (MartínFontecha et al., 2004) . We found that NK cells entered the LN readily in tumorbearing RAG / mice receiving CD4 + T cells but not in RAG /  c / mice, untreated RAG / mice, or NKdepleted RAG / mice (Fig. 6 D) . These data suggest that NK cells are not required for activation of naive tumorspecific CD4 + T cells in vivo.
 c signaling on host cells is required for the proper activation, differentiation, and survival of naive tumorspecific TRP-1 CD4 + T cells in vivo
We were perplexed as to why RAG /  c / mice failed to control tumor immunity even when WT NK cells were present. TRP1 CD4 + T cells were analyzed 1 wk after transfer from RAG / and RAG /  c / hosts. Expression of CD62L was low on both populations, indicating activa tion in vivo ( Fig. 7 A) . However, CD122, ICOS, and CD25 were expressed at lower levels on TRP1 CD4 + T cells from RAG /  c / hosts when compared with TRP1 CD4 + T cells from RAG / mice (Fig. 7 A) . Consistent with these findings, IFN and the CXCR3 ligand CXCL9, but not CXCL10, were lower in the serum of RAG /  c / hosts ( Fig. 7 B and not depicted) . Surprisingly, 1 wk after therapy, there were more TRP1 CD4 + T cells in RAG /  c / hosts than in RAG / hosts (Fig. 7 C) , which is in agree ment with recent findings by others (Guimond et al., 2009) . We therefore looked at other time points in vivo and found that TRP1 CD4 + T cells failed to persist after 4 wk in RAG /  c / lymphopenic hosts (Fig. 7 C) . Looking at other parameters, we found that TRP1 CD4 + T cells from RAG / mice produced IFN, but not IL17, when stimulated ex vivo. However, TRP1 CD4 + T cells from RAG /  c / mice failed to produce IFN or IL17 (Fig.  7 D) . Because failure to produce IFN may be related to their failure to differentiate, we stained for the Th1 tran scription factor Tbet and found that expression was consid erably lower in TRP1 CD4 + T cells from RAG /  c / hosts (Fig. 7 E) . Further exploration showed that CD11c high DCs expressed less MHC class II and CD80 but similar lev els of CD40 in RAG /  c / hosts when compared with RAG / hosts (Fig. 7 F) . Lastly, it was possible that trans ferred TRP1 CD4 + T cells could have converted to T reg cells, which lead to tumor progression, but that was not evi dent beyond 4 wk after therapy (Fig. S4) .
Collectively, the data suggest that  c signaling on host cells may be required for proper activation of naive CD4 + T cells. This may occur through IL12 signals that increase class II and CD80 expression on host DCs (Ohteki et al., 2001 (Ohteki et al., , 2006 Terme et al., 2008) . Consistent with this, MHC class II and CD80 were decreased in RAG /  c / hosts receiving TRP1 CD4 + T cells. These experiments suggest that lack of  c sig naling, possibly on host DC, in RAG /  c / mice might hinder proper activation of adoptively transferred naive TRP1 CD4 + T cells, which eventually leads to their failure to sur vive and maintain treatment of established tumors. T cells, which is not dependent on NK cells. RAG /  c / mice express low levels of MHC class II and CD80 on CD 11c high cells, both of which may be needed to properly activate CD4 + T cells in vivo. The availability of MHC class II on APC has already been shown to be critical in regulating the homeo static proliferation of CD4 + T cells (Kassiotis et al., 2003) . Therefore, removing DC cells by highintensity lymphode pleting regimens may harm ACT with CD4 + T cells. As seen in other studies, adding these cells back with lymphodepleting regimens may enhance immunotherapy (Dubsky et al., 2007; Palucka et al., 2007; Banchereau et al., 2009) .  c signaling is part of the IL2 cytokine family, which in cludes IL4, IL7, IL9, IL15, and IL21. Increased IL7 and IL15 levels in the host have been shown in the clinic and in animal models to be the mechanisms by which lymphodeplet ing regimens enhance adoptive immunotherapy (Gattinoni et al., 2005a; Dudley et al., 2008; Guimond et al., 2009) . How ever, it has not been shown in a reciprocal manner that the host needs  c signaling for efficient activation of tumorspecific T cells. We observed that with loss of  c , CD4 + T cell differ entiation and survival were diminished by wk 4 after transfer. In RAG /  c + hosts, we saw expansion and survival of CD4 + T cells past 4 wk. We also found higher expression of MHC class II on CD11c high CD86 high DC and the Th1 tran scription factor Tbet in TRP1 CD4 + T cells isolated from RAG / mice when compared with TRP1 CD4 + T cells from RAG /  c / mice. Our results differ from those in a recent study showing that  c signaling on DC reduces CD4 + T cell homeostatic proliferation in vivo (Guimond et al., 2009) . We found that TRP1 CD4 + T cells expand initially at 1 wk after adoptive cell transfer but fail to survive in RAG /  c / hosts once tumor progresses, which is usually 4 wk or later. Surprisingly, even though there were more tumorspecific T cells in RAG /  c / hosts, it was not enough to clear tumor. It may be possible that strong (selfreactive) TCR activation is a prerequisite for survival for selfreactive TRP1 CD4 + T cells because the previous study used polyclonal CD4 + T cells or antigenspecific CD4 + T cells that do not recognize an an tigen in the host (Guimond et al., 2009) . This strong activation (indicated by CD5 expression on TRP1 CD4 + T cells) may come from increased expression of CD80 and MHC class II on DC that requires  c for their activation to become sensitive to and produce IL12, which is paramount for Th1 priming in vivo (Ohteki et al., 2001 (Ohteki et al., , 2006 Terme et al., 2008) . During in vivo differentiation, TRP1 CD4 + T cells expressed high lev els of IL12R1 and IL27R during in vivo differentiation, which are required for priming, and IL23R, which may be important for Th1 memory formation. The strong up regulation of Stat4 in TRP1 T cells in vivo shows that IL12 and/or IL23 signals are driving their activation, as indicated by high IFN production and IL22, respectively. This is fur ther supported by lack of IFN and Tbet expression in TRP 1 CD4 + T cells isolated from RAG /  c / hosts 4 wk after transfer in addition to lack of IFN and CXCL9, but not CXCL10, in the serum at 1 wk in RAG /  c / hosts. There fore, it appears that lack of proper DC activation leads to low Walker, 1998; Ridge et al., 1998; Diehl et al., 1999) , but the mechanisms by which CD4 + T cells cause eradication of es tablished tumors by themselves are still unknown.
Previously it was shown that CD4 + T cells could prevent the growth of tumors by antiangiogenesis through the activa tion of IFNR on nonhematopoietic cells. However, this action was not shown for large vascularized tumors in a treat ment and adoptive cell transfer model and it was not clear whether CD8 + T cells were involved (Qin and Blankenstein, 2000) . Rejection of small tumors was also shown to be an in direct process through IFN-dependent activation of mac rophages or by eosinophils and NK cells (Hung et al., 1998; Corthay et al., 2005) . We noted high levels of CCL11 in the serum during treatment and CCL24 expression by TRP1 CD4 + T cells, which are known to recruit eosinophils, so their role cannot be excluded. Indirect effects of CD4 + T cells have also been noted in a study using Tg Marylyn CD4 + T cells, which recognize the male antigen HY. MHC class II  tumors were amenable to treatment and this was at tributed to NK cells (PerezDiez et al., 2007) . In this paper, we do not find a role for NK cells in this model.
Not surprisingly, with adoptive cell transfer therapies using in vitro differentiated CD4 + T cells to treat large vascularized tumors, IFNR / mice were shown not to respond to treatment (Muranski et al., 2008) , and anti-IFN diminished the antitumor effect (Nishimura et al., 1999; Muranski et al., 2008) . However, IFN / mice were able to respond to treatment with in vitro differentiated CD4 + T cells, indicating that the innate source of IFN (NK cells) was not needed (Qin and Blankenstein, 2000; Muranski et al., 2008) . Because we saw increased MHC class II expression in the tumor mi croenvironment, it is possible that IFN from CD4 + T cells may be needed to increase MHC class II expression on tumor cells, which allows a direct interaction between T cells and cancerous cells to occur (Quezada et al., 2010) . Direct killing of tumors is possible, as indicated by high granzyme B expres sion by TRP1 CD4 + T cells on gene microarray and expres sion of perforin, granzyme B, and LAMP1 in TRP1 CD4 + T cells isolated from the spleen. IFN may be working indi rectly at a local level through macrophages expressing NO, TNF, ROS, and NKG2D receptors (Kahn et al., 1991; Raulet and Guerra, 2009) . IFN released by differentiated CD4 + T cells may be so extremely high in the tumor microenviron ment that the tumor vasculature expressing IFN receptors undergoes antiangiogenesis. The presence of specific disease, indicated by depigmentation and uveitis (Muranski et al., 2008) , supports the theory of a direct killing mechanism against MHC class II + cells. Inflammatory monocytes in the tumor microenvironment may also play an indirect role in the process. Another unappreciated role of IFN may be to in duce the chemokines CXCL9 and CXCL10 (Luster et al., 1985) , which may be required to attract CXCR3 + antitumor CD4 + T cells into the tumor site. Most importantly, all of these mechanisms may not be mutually exclusive.
Why then does tumor therapy fail in RAG /  c / mice? CD4 + T cells need to become properly activated cytotoxic et al., 2007) . It can also break tolerance to a poorly immuno genic tumor (Wilcox et al., 2002) . ICOS is being considered as another immunotherapy candidate (Paulos, C. and June, C., personal communication) . These therapies could be com bined with ACT in the future.
In this study, we focused on naive CD4 + T cells, which differentiate properly in their natural state and become long lived memory T cells. This idea was also demonstrated in an other tumor model that involved activation of naive T cells via forced LIGHT expression in the tumor microenviron ment (Yu et al., 2004) . Although forced expression of LIGHT in human tumors may not be a clinical reality, this led to a profound tumor rejection indicating the importance of acti vating naive T cells in their natural state.
How do you obtain naive T cells from humans? TCR transduction of naive T cells with CD4 + MHC class II tumor specific TCRs could be attempted in humans, as previously achieved with MHC class I tumorspecific TCRs (Morgan et al., 2006; Hinrichs et al., 2009) . It may be possible to trans fer naive tumorspecific CD4 + T cells into hosts precondi tioned with noninvasive cytokine therapies that do not cause harmful side effects. Transduction of high avidity TCRs to tumor antigens into naive or cord PBL is feasible and may be augmented by high doses of IL7 or IL15 administration plus antiCTLA or anti41BB therapy.
How do you obtain nontolerant highly reactive TCRs as seen in this paper? Mouse TCRs reactive against human can cer antigens can be transfected into human T cells using gene therapy (Johnson et al., 2009) . Human HLA Tg mice can be immunized with human cancer antigens to generate highly tumorreactive TCRs, which can then be used in the immuno therapy of cancer in humans.
In summary, TRP1 Tg mice represent a new ACT im munotherapy model for the study of ways to induce potent antitumor immunity against established melanoma without the need for cytotoxic CD8 + T cells or a vaccine. Understanding the mechanisms of tumor regression in mice with lymphope nia may allow the development of new therapies that work in the absence of chemotherapy and radiation. These data suggest a new role for CD4 + T cells as cytotoxic T cells.
MATERIALS AND METHODS
Mice. Tyrp1 B-w RAG / TRP1specific CD4 + TCR Tg mice (B6.Cg Rag1 tm1Mom Tyrp1 B-w Tg(Tcra,Tcrb)9Rest/J; deposited at The Jackson Labora tory) and WT Tyrp1 +/+ TRP1specific CD4 + TCR Tg mice were created by P.A. Antony and K. Irvine at the National Cancer Institute (Bethesda, MD; Muranski et al., 2008) . Recombinationactivating gene 1 / (Rag1 tm1Mom ) mice, Foxp3 sf , C57BL/6 WT, and MHC class II / were purchased from The Jackson Laboratory. RAG /  c / mice were purchased from Taconic (Cao et al., 1995) . Foxp3 sf mice were crossed with Tyrp1 +/+ TRP1specific CD4 + TCR Tg mice to generate Tyrp1 +/+ TRP1specific CD4 + TCR Foxp3 sf Tg mice. All mice were used in accordance with guidelines from the University of Maryland Institutional Animal Care and Use Committee. All experiments were conducted with the approval of the Animal Use and Care Committees of the National Cancer Institute, Johns Hopkins University School of Medicine, and the University of Maryland School of Medicine.
Tumor lines and measurement. B16.F10 (H2 b ), hereafter called B16, is a TRP1 + spontaneous murine melanoma that was obtained from ATCC expression of MHC class II and CD80, which subsequently leads to inappropriate activation of naive TRP1 CD4 + T cells in RAG /  c / hosts. Loss of IFN expression by CD4 + T cells possibly leads to loss of CXCL9 expression in the tissues, and this may lead to failure of recruitment of anti tumor CXCR3 + CD4 + T cells to the tumor site. This pattern of recruitment may be similar to the process that occurs dur ing nephritis or disease of the eye during herpes simplex virus type 1 infection, which requires CXCL9, but not CXCL10, for recruitment of CXCR3 + T cells into the tissues (Wuest et al., 2006; Menke et al., 2008) .
Why seek to understand how TRP1 CD4 + T cells are activated in vivo? More intense ablation may remove DCs that provide the secondary signals (such as IL12 or possibly IL23) that are needed to properly differentiate CD4 + T cells in vivo into longlived memory cells, which is similar to IL2 for CD8 + T cells (Williams et al., 2006) . Less space may be the Achilles' heel of intense lymphodepletion when using CD4 + T cells. This may indicate that CD4 + T cells are not receiving the proper signals initially for longlived survival. In mice ir radiated with 9 Gy and humans receiving 12 Gy lymphode pleting regimens, IL2 administration was needed to augment ACT. Transfer of naive T cells has not yet been accomplished in these settings. These cells may require administration of DC for support (Steinman and Banchereau, 2007) .
How can this environment be obtained without lympho depleting chemotherapy or irradiation? Cytokines (such as IL7 and IL15) found in patients receiving highdose radia tion therapy and irradiated WT and RAG / mice may be used to mimic lymphopenia in a WT host (Gattinoni et al., 2005a; Zhang et al., 2005; Guimond et al., 2009; Pellegrini et al., 2009) . In humans, IL7 has shown strong promise in recent years, and long administration has been shown to release the inhibitory networks that suppress antitumor im munity (Pellegrini et al., 2009) . Cytokine/antibody immune complexes to IL2, IL7, or IL15 may offer another way to mimic lymphopenia, as a much lower amount of cytokines is needed to enhance proliferation of naive and memory phenotype T cells in vivo (Boyman et al., , 2008 Rubinstein et al., 2006; Cho et al., 2007) . Lymphopenia induced activation of CD4 + T cells itself may program these cells to become less prone to tolerance induction seen in other systems using CD4 + T cells (Sotomayor et al., 1999) , and we are currently exploring this.
Administration of antibodies against costimulatory and inhibitory molecules is another method to enhance antitumor immunity. We saw high expression of CTLA4 and 41BB on TRP1 CD4 + T cells. Anti-CTLA4 therapy is being used in clinical trials and has been shown to enhance adoptive cell therapies already with CD8 + T cells and donor lympho cyte infusions by inhibiting T reg cells and enhancing activa tion of non-T reg cells (Quezada et al., 2006 (Quezada et al., , 2008 Peggs et al., 2009) . With tumorspecific TRP1 CD4 + T cells, this enhances therapy considerably in WT and lymphopenic hosts (Quezada et al., 2010) . Stimulation of 41BB also enhances immunotherapy using T cells coexpressing 41BBL (Stephan complementary RNA was purified using RNeasy micro kit (QIAGEN) and followed by quantification of both concentrations of complementary RNA and dye labeled. RNA spikein controls (Agilent Technologies) were added to RNA samples before amplification and labeling according to the manu facturer's protocol. The entire amount of each sample labeled with Cy3 or Cy5 was mixed with control targets (Agilent Technologies). Fragmentation was performed by incubating at 60°C for 30 min and stopped by adding an equal volume of 2× GE HiRPM hybridization buffer (Agilent Technolo gies). Agilent 4X44K whole mouse genome array (G4122F) with 41534 unique probes was used. Fragmented targets were added onto a microarray, assembled into a hybridization chamber (Agilent Technologies), and hybrid ized at 60°C for 17 h in a hybridization oven with rotation. Hybridized microarrays were washed and dried according to the Agilent microarray processing protocol. Microarrays were scanned using an Agilent G2505B Scanner controlled by Agilent Scan Control 7.0 software. Data were ex tracted with Agilent Feature Extraction 9.1 software. Differentially expressed targets were identified using the processed data and the log ratio generated by the software. Only values of twofold or higher were reported. Heat maps were hand generated from the gene lists. The GEO microarray data acces sion no. is GSE19904.
Measurement of serum cytokines and chemokines.
Serum was collected via tail vein using serum collection tubes (BD). Serum was ana lyzed by MILLIPLEX 32Plex assay (University of Maryland, Baltimore, Cytokine Core Laboratory, and Millipore).
Statistics. An unpaired Student's t test was used to compare the differences between cytokines and chemokines as indicated. Tumor curves were com pared using a twoway ANOVA with nonrepeated measures. Pvalues of ≤0.05 were considered significant. PRISM 5.0b software was used to analyze the data (GraphPad Software, Inc.).
Online supplemental material. Fig. S1 shows the phenotype of TRP1 Tg WT, Foxp3 sf , and tyrp1 B-w mice. Fig. S1 also shows that TRP1 CD4 + cells are activated in WT mice but not in tyrp1 B-w mice. Foxp3 expression in naive TRP1 CD4 + T cells from tyrp1 B-w RAG / mice is shown. Lastly, tumor infiltration by TRP1 CD4 + T cells is shown by flow cytometry. Fig. S2 shows accumulation of inflammatory monocytes in the spleen, LN, and tumor after adoptive transfer of TRP1 CD4 + T cells into tumorbearing lymphopenic mice. Fig. S3 shows stable expression of Foxp3 in TRP1 CD4 + T cells after tumor treatment. Fig. S4 shows that TRP1 CD4 + T cells do not convert to Foxp3 + cells in RAG /  c / tumorbearing hosts during tumor progression. Online supplemental material is available at http://www .jem.org/cgi/content/full/jem.20091921/DC1. and maintained in culture media as previously described (Antony et al., 2006) . Tumors were injected subcutaneously at 2 × 10 5 cells/mouse. Tumors are measured blindly with digital calipers. The perpendicular diameters are determined and multiplied to generate the area in millimeters squared as previously described (Antony et al., 2006) .
Sorting and adoptive cell transfer. TRP1 CD4 + T cells were sorted from spleens of donor Tyrp1 B-w RAG1 / TRP1-specific Tg male mice. Spleens were harvested and made into singlecell suspensions. Cells were made devoid of red blood cells by ACK lysis. Subsequently, cells were counted and enriched for CD4 + T cells by magnetic bead sorting using a CD4 + T cell enrichment kit from Miltenyi Biotec. Enriched CD4 + T cells were counted and resuspended in PBS and used in adoptive transfer studies (2 × 10 5 cells/mouse). NK cells were isolated from WT mice using NK cell sorting kits from Miltenyi Biotec. When indicated, 5 × 10 6 NK cells were transferred on the same day as TRP1specific T cells. Openrepertoire CD4 + CD25  T cells from WT mice were sorted as previously described (Antony et al., 2006) . Mice were irradiated as previously described .
Depleting antibodies. Anti-IFN (XMG1.2, NA/LE) and antiNK1.1 (NA/LE, PK136) were purchased from BD.
Flow cytometry. AntiCD4 (RM45), antiCD25 (PC61), antiCD122 (TM1), antiV14 (14-2), antiNK1.1 (PK136), antiICOS (7E.17G9), antiCD44 (IM7), antiCD62L (MEL14), antiCD11c (HL3), antiCD86 (GL1), anti-MHC class II (AF6120.1), anti-IL17 (TC1118H10), anti-IFN (XMG1.2), antiTNF (MP6XT22), antiCD49b (DX5), and CD11b (M1/70) were obtained from BD. Anti-IL7R (SB/199), antiCXCR3 (CXCR3173), antiFoxp3 (FJK16s), antiTbet (4B10), anti-MHC class II (IA/IE; M5/114.15.2), anti-GR1 (RB68C5), anti perforin (eBioOMAKD), antiNKp46 (29A1.4), antiLAMP1 (1D4B), anti-granzyme B (16G6), and antiNKG2D (CX5) were obtained from eBioscience. All flow cytometry scales are log scales, if not otherwise speci fied. Intracellular staining for cytokines was done with the Cytofix/ Cytoperm intracellular staining kit (BD). For granzyme B, Foxp3, and perforin, the Foxp3 staining buffer set was used as recommended by eBioscience. All samples were run on a FACSCalibur (BD; Department of Surgery, University of Maryland School of Medicine) and analyzed by FlowJo Software (Tree Star, Inc.).
Confocal microscopy.
Confocal microscopy was done as previously de scribed (Quezada et al., 2008) except that slides were imaged on an LSM (Olympus) with a 20× oil immersion objective. In brief, tumor was frozen in OCT solution (Sakura). 8µm sections were cut with a microcryotome (Leica), fixed for 10 min in cold acetone, allowed to air dry, hydrated with PBS for 5 min, and then blocked with PBS with 2% FCS, 50 µg/ml 24G2 antibodies, and 5% rat, hamster, and mouse serum for 15 min. Slides were stained overnight with anti-MHC class II APC and DAPI, washed, and mounted. Samples were scanned on an inverted confocal microscope (LSM; University of Maryland Greenebaum Cancer Center) under a 20× oil im mersion objective. Images were analyzed with Image J64 software (National Institutes of Health).
Gene microarrays. RNA was isolated from FACSsorted CD4 + T cells from LN and spleens of tumorbearing RAG / mice undergoing treatment with TRP1 CD4 + T cells. RNA was isolated with RNA isolation kits (QIAGEN). Sample amplification and labeling procedures were performed using a Low RNA Input Fluorescent Linear Amplification kit (Agilent Technologies). In brief, 400 ng of total RNA was used as starting material base on available yield of RNA isolation but was kept at the same amount of input in each experiment. Total RNA was reverse transcribed into first strand and secondstrand complementary DNA by MMLVRT using an oligodT primer that incorporates a T7 promoter sequence. The comple mentary DNA was then used as a template for in vitro transcription in the presence of T7 RNA polymerase and cyaninelabeled CTPs. The labeled
